基于伊马替尼治疗系统性硬化症疗效的meta分析

doi:10.5246/jcps.2019.03.019

中国药学(英文版) ›› 2019, Vol. 28 ›› Issue (3): 195-202.DOI: 10.5246/jcps.2019.03.019

• 【药事管理与临床药学专栏】 • 上一篇下一篇

基于伊马替尼治疗系统性硬化症疗效的meta分析

张琪, 张博, 林能明^*

南京医科大学附属杭州医院, 杭州市医学转化研究中心, 浙江杭州 310006

收稿日期:2018-11-05 修回日期:2019-01-16 出版日期:2019-03-30 发布日期:2019-02-20
通讯作者: Tel.: +86-571-56007905; Fax: +86-571-87914773, E-mail: lnm1013@163.com
基金资助:
Hangzhou Major Science and Technology Project (Grant No. 20172016A01), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents (Grant No. 2010-190-4), Clinical Pharmacy of Zhejiang Medical Key Discipline (Grant No. 2018-2-3) and Clinical Pharmacy of Hangzhou Medical Key Discipline (Grant No. 2017-68-7).

Implications for the therapeutic role of Imatinib in systemic sclerosis: a single-arm meta-analysis

Qi Zhang, Bo Zhang, Nengming Lin^*

Hangzhou Translational Medicine Research Center, Affiliated Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou 310006, China

Received:2018-11-05 Revised:2019-01-16 Online:2019-03-30 Published:2019-02-20
Contact: Tel.: +86-571-56007905; Fax: +86-571-87914773, E-mail: lnm1013@163.com
Supported by:
Hangzhou Major Science and Technology Project (Grant No. 20172016A01), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents (Grant No. 2010-190-4), Clinical Pharmacy of Zhejiang Medical Key Discipline (Grant No. 2018-2-3) and Clinical Pharmacy of Hangzhou Medical Key Discipline (Grant No. 2017-68-7).

摘要/Abstract

摘要：

硬皮病样慢性移植物抗宿主病(ScGVHD)或系统性硬化症(SSc)是慢性移植物抗宿主病中最严重的临床表现之一。目前, SSc仍缺少有效的临床治疗方法和干预手段。研究发现伊马替尼(酪氨酸激酶抑制剂)对ScGVHD或SSc存在潜在治疗效果, 但其有效性始终存在争议。本文旨在运用meta分析对其有效性进行系统性的评价。研究发现, 伊马替尼治疗组中肺部受累的SSc患者的临床缓解率(CRR = 0.601)高于无肺部受累患者(P<0.001), 病程长的SSc患者的临床缓解率(CRR = 0.550)高于病程短的患者(P<0.001)。简言之, 伊马替尼可在一定程度上有效缓解SSc, 故可为以后SSc的临床治疗提供新的参考价值。

关键词: 伊马替尼, 系统性硬化症, 硬化性慢性移植物宿主病

Abstract:

Sclerotic chronic graft-versus-host disease (ScGVHD) or systemic sclerosis (SSc) is one of the most severe manifestations of chronic graft-versus-host disease (cGVHD) since the involvement of major organs significantly affects the mortality and morbidity of SSc patients. Currently, there are no effective therapeutic approaches or standard “second-line” therapy for SSc. Imatinib, a clinical tyrosine kinase inhibitor used to treat chronic myeloid leukemia and gastrointestinal tumor, has shown potential therapeutic effects in treating ScGVHD or SSc. Due to the current limitations of clinical trials using Imatinib in the treatment of SSc, the results vary among different studies, and the applications of Imatinib in SSc is still in vagueness. Here we conducted a single-arm meta-analysis to quantitatively and systematically interpret the results of previous studies, as to evaluate the potential therapeutic effect of Imatinib in SSc. The pooled clinical response rate (CRR) showed that Imatinib had higher CRR in SScpatients with longer disease duration (CRR = 0.550) and lung involvement (CRR = 0.601) than those without (P<0.001). Therefore, it was encouraging to conduct future clinical studies regarding Imatinib therapy in SSc patients, since the global response rate of Imatinib was higher than expected in specific subgroup patients.

Key words: Imatinib, Systemic sclerosis, Sclerotic chronic graft-versus-host disease

中图分类号:

R954

Supporting:

张琪, 张博, 林能明. 基于伊马替尼治疗系统性硬化症疗效的meta分析[J]. 中国药学(英文版), 2019, 28(3): 195-202.

Qi Zhang, Bo Zhang, Nengming Lin. Implications for the therapeutic role of Imatinib in systemic sclerosis: a single-arm meta-analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(3): 195-202.

参考文献

[1] Jaeger, V.K.; Wirz, E.G.; Allanore, Y.; Riemekasten, G.; Hachulla, E.; Distler, O.; Airò, P.; Carreira, P.E.; Tikly, M.; Vettori, S.; Balbir Gurman, A.; Damjanov, N.; Müller-Ladner, U.; Distler, J.H.W.; Li, M.; Häusermann, P.; Walker, U.A. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis - A 10 year longitudinal study from the eustar database. Ann. Rheum. Dis. 2016, 75, 1285-1292.

[2] Gordon, J.K.; Domsic, R.T. Clinical Trial Design Issues in Systemic Sclerosis: an Update. Curr. Rheumatol. Rep. 2016, 18, 38.

[3] Kowal-Bielecka, B.O.; Landewe, R.; Avouac, J.; Chwiesko, S.; Miniati, I.; Czirjak, L.; Clements, P.;Denton, C.; Farge, D.; Fligelstone, K.; Foldvari, I.; Furst, D.E.; Muller-Ladner, U.; Seibold, J.; Silver, R.M.; Takehara, K.; Toth, B.G.; Tyndall, A.; Valentini, G.; van den Hoogen, F.; Wigley, F.; Zulian, F.; Matucci-Cerinic, M. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. 2009, 68, 620-628.

[4] Fraser, C.J.; Scott Baker, K. The management and outcome of chronic graft-versus-host disease. Br. J. Haematol. 2007, 138, 131-145.

[5] Guo, L.; Chen, X.X.; Gu, Y.Y.; Zou, H.J.; Ye, S. Low-dose imatinib in the treatment of severe systemic sclerosis: A case series of six Chinese patients and literature review. Clin. Rheumatol. 2012, 31, 1395-1400.

[6] Tian, H.P.; Zhang, J. Efficacy and safety of homoharringtonine during consolidation therapy in chronic myeloid leukemia: A meta-analysis. J. Chin. Pharm. Sci. 2014, 23, 716-722.

[7] Dimitroulas, T.; Daoussis, D.; Garyfallos, A.; Sfikakis, P.P.; Kitas, G.D. Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis. Curr. Med. Chem. 2015, 22, 1943-1955.

[8] Korman, B.D.; Criswell, L.A. Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance. Curr. Rheumatol. Rep. 2015, 17, 21.

[9] Assassi, S.; Wu, M.H.; Tan, F.K.; Chang, J.; Graham, T.A.; Furst, D.E.; Khanna, D.; Charles, J.; Ferguson, E.C.; Feghali-Bostwick, C.; Mayes, M.D. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum. 2013, 65, 2917-2927.

[10] Khanna, D.; Saggar, R.; Mayes, M.D.; Abtin, F.; Clements, P.J.; Maranian, P.; Assassi, S.; Saggar, R.; Singh, R.R.; Furst, D.E. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011, 63, 3540-3546.

[11] Spiera, R.F.; Gordon, J.K.; Mersten, J.N.; Magro, C.M.; Mehta, M.; Wildman, H.F.; Kloiber, S.; Kirou, K.A.; Lyman, S.; Crow, M.K. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann. Rheum. Dis. 2011, 70, 1003-1009.

[12] Magro, L.; Mohty, M.; Catteau, B.; Coiteux, V.; Chevallier, P.; Terriou, L.; Jouet, J.P.; Yakoub-Agha, I. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood. 2009, 114, 719-722.

[13] Pope, J.; McBain, D.; Petrlich, L.; Watson, S.; Vanderhoek, L.; de Leon, F.; Seney, S.; Summers, K. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 2011, 63, 3547-3551.

[14] Arai, S.; Pidala, J.; Pusic, I.; Chai, X.Y.; Jaglowski, S.; Khera, N.; Palmer, J.; Chen, G.L.; Jagasia, M.H.; Mayer, S.A.; Wood, W.A.; Green, M.; Hyun, T.S.; Inamoto, Y.; Storer, B.E.; Miklos, D.B.; Shulman, H.M.; Martin, P.J.; Sarantopoulos, S.; Lee, S.J.; Flowers, M.E.D. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clin. Cancer Res. 2016, 22, 319-327.

[15] Baird, K.; Comis, L.E.; Joe, G.O.; Steinberg, S.M.; Hakim, F.T.; Rose, J.J.; Mitchell, S.A.; Pavletic, S.Z.; Figg, W.D.; Yao, L.; Flanders, K.C.; Takebe, N.; Sarantopoulos, S.; Booher, S.; Cowen, E.W. Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease. Biol. Blood Marrow Transplant. 2015, 21, 1083-1090.

[16] Fraticelli, P.; Gabrielli, B.; Pomponio, G.; Valentini, G.; Bosello, S.; Riboldi, P.; Gerosa, M.; Faggioli, P.; Giacomelli, R.; Del Papa, N.; Gerli, R.; Lunardi, C.; Bombardieri, S.; Malorni, W.; Corvetta, A.; Moroncini, G.; Gabrielli, A. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res. Ther. 2014, 16, R144.

[17] Olivieri, A.; Locatelli, F.; Zecca, M.; Sanna, A.; Cimminiello, M.; Raimondi, R.; Gini, G.; Mordini, N.; Balduzzi, A.; Leoni, P.; Gabrielli, A.; Bacigalupo, A. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009, 114, 709-718.

[18] Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25, 603-605.

[19] Desbois, A.C.; Cacoub, P. Systemic sclerosis: An update in 2016. Autoimmun. Rev. 2016, 15, 417-426.

[20] Murdaca, G.; Contatore, M.; Gulli, R.; Mandich, P.; Puppo, F. Genetic factors and systemic sclerosis. Autoimmun. Rev. 2016, 15, 427-432.

[21] Yanaba, K. Strategy for treatment of fibrosis in systemic sclerosis: Present and future. J. Dermatol. 2016, 43, 46-55.

[22] Khanna, D.; Denton, C.P.; Jahreis, A.; van Laar, J.M.; Frech, T.M.; Anderson, M.E.; Baron, M.; Chung, L.; Fierlbeck, G.; Lakshminarayanan, S.; Allanore, Y.; Pope, J.E.; Riemekasten, G.; Steen, V.; Müller-Ladner, U.; Lafyatis, R.; Stifano, G.; Spotswood, H.; Chen-Harris, H.; Dziadek, S.; Morimoto, A.; Sornasse, T.; Siegel, J.; Furst, D.E. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016, 387, 2630-2640.

[23] Wells, A.U.; Denton, C.P. Interstitial lung disease in connective tissue disease: Mechanisms and management. Nat. Rev. Rheuml. 2014, 10, 728-739.

[24] Sabnani, I.; Zucker, M.J.; Rosenstein, E.D.; Baran, D.A.; Arroyo, L.H.; Tsang, P.; Zubair, M.; Rivera, V. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford). 2009, 48, 49-52.

[25] Castillo-Tandazo, W.; González, J.; Flores-Fortty, A. Pathogenesis and therapeutics of interstitial lung disease in systemic sclerosis. Curr. Rheumatol. Rev. 2013, 9, 105-112.

[26] Steen, V.D.; Medsger, T.A., Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000, 43, 2437-2444.

基于伊马替尼治疗系统性硬化症疗效的meta分析

Implications for the therapeutic role of Imatinib in systemic sclerosis: a single-arm meta-analysis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	周毅, 吴星烨, 李娟, 程伟, 李小松, 沈依帆, 张军. 药师在胃肠间质瘤多学科诊疗团队中的作用[J]. 中国药学(英文版), 2021, 30(7): 598-605.
[2]	周毅, 赖俊莉, 邱峰, 张军. 高效液相色谱法常规监测中国胃肠间质瘤患者体内的伊马替尼血药浓度[J]. 中国药学(英文版), 2020, 29(9): 637-648.